Michael J Kozal MD

Professor of Medicine (AIDS); Chief Section of Infectious Diseases VA CT Healthcare System; Director Yale HIV Clinical Trials; Acting Chief, Medical Service VACHS & Vice Chair, VA Medical Service for the Yale Dept. of Internal Medicine

Research Interests

Genetic determinants of HIV and Hepatitis C drug resistance; New technologies to detect low abundance drug resistant viral variants

Research Summary

Dr. Kozal's major research interests are the genetic determinants of HIV and Hepatitis C drug resistance. Dr. Kozal’s lab uses new deep sequencing technologies to detect minority resistant viral variants in patients and study the impact of these resistant variants on clinical outcomes. Dr. Kozal is the Director of HIV Clinical Trials at Yale and the VA and he is the principal investigator on multiple HIV and Hepatitis C clinical trials.

Selected Publications

  • Zou Xiaobai, Chen Xi, Tian H, Williams AB, Wang H, He J, Zhen J, Chiarella J, and Kozal MJ. Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China. PLoS One. 2014 Jun 4;9(6):e98740. doi: 10.1371/journal.pone.0098740
  • Chabria S, Gupta S and Kozal MJ. Deep Sequencing of HIV: clinical and research applications. Annual Review of Genomics and Human Genetics. 2014 May 9. [Epub ahead of print] PMID: 24821496
  • Li JZ, Paredes R, Ribaudo H, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen M, Huppler Hullsiek K, Ostergaard L, Miller MD, and Kuritzkes DR. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype after Virologic Failure. Journal of Infectious Diseases, 2013 Mar;207(6):893-7. PMID:23264671
  • Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R. A study of financial incentives to reduce plasma HIV RNA among patients in care. AIDS Behav. AIDS Behav. 2013 Sep17(7):2293-300. PMID: 23404097
  • Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA. Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. Addict Med. 2013 Mar-Apr;7(2):102-7. PMID:23388678
  • Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, Benetucci J, Mancini M, Yang R, Wirtz V, Percival L, Zhang J, Zhu L, Arikan D, Farajallah A, Nguyen BY, Leavitt R, McGrath D, and Lataillade M for the SPARTAN study team. A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir 300mg BID Plus Raltegravir 400mg BID in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results. HIV Clin Trials. 2012 May-Jun;13(3):119-30. PMID:22592092
  • Winters MA, Lloyd RM Jr, Shafer RW, Kozal MJ, Miller MD, et al. (2012) Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations. PLoS ONE 7(7): e40514. doi:10.1371/journal.pone.0040514
  • Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St. John E, Moreno E and Kozal M. Virologic Failures on Initial boosted-PI Regimen Infrequently Possess Low-level Variants with Major PI Resistance Mutations by Ultra-deep Sequencing. PLoS One 2012;7(2):e30118. PMID: 22355307
  • Li JZ, Paredes R, Ribaudo H, Svarovskaia ES, Kozal MJ, et al. Relationship between Minority NNRTI Resistance Mutations, Adherence, and the Risk of Virologic Failure. AIDS. 2012 Jan 14;26(2):185-92. PMID: 22179227
  • Li JZ, Paredes R, Ribaudo H, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Minority HIV-1 Drug Resistance Mutations and the Risk of NNRTI-based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis. JAMA, 2011;305(13):1327-1335.


Edit Profile